Dimerix Limited
1 day chart
Get A$10 trading credit to start you off
Sign up and fund a new Stake AUS account and enjoy an extra A$10 trading credit on us.
Sign up and fund a new Stake AUS account and get A$10 bonus trading credit.
T&Cs apply
About DXB
Dimerix Limited (DXB) is a biopharmaceutical company in the clinical development phase, working to support patients affected by inflammation-related conditions, including kidney-related disorders. The company is currently advancing its drug candidate DMX-200, in Phase 3 trials for Focal Segmental Glomerulosclerosis (FSGS), a kidney condition, and is also progressing DMX-700, targeting respiratory conditions. Both DMX-200 and DMX-700 were identified using Dimerix's drug discovery method known as Receptor Heteromer Investigation Technology (Receptor-HIT) - a platform that supports the analysis of receptor interactions to find new drug possibilities.
Find out what a historical investment in Dimerix Limited would be worth today using our DXB stock calculator.
Sector
Health Care
CEO
-
Industry
Biotechnology
Website
dimerix.com
$318M
-14.59
-
$0.56
$0.53
$0.55
$0.79
$0.30
Ready to start your investing journey with Stake?
Open an accountAnnouncements
DXB FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in DXB
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in DXB
on Stake
Buy DXB from A$3 brokerage
Invest in 2,500+ Aussie stocks and ETFs
CHESS-sponsored ASX trades
